.Attributes Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of clients along with HER2+ sophisticated bosom cancer as well as active or stable brain metastases showed consistent intracranial task as well as systemic efficacy of T-DXd.